 VANCOUVER, British Columbia--BUSINESS WIRE--Zymeworks Inc. NYSE:ZYME, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission EC has granted Orphan Drug designation for zanidatamab, the companys investigational HER2-targeted bispecific antibody, in patients with gastric cancer. We are encouraged by the European Commissions and European Medicines Agencys recognition of the benefit that zanidatamab can provide i 